The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

NARecruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2026

Conditions
Immune Thrombocytopenia With Positive ANA Antibodies
Interventions
DRUG

Hydroxychloroquine Oral Tablet

Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.

DRUG

Eltrombopag

Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.

Trial Locations (7)

200032

RECRUITING

Shanghai Zhongshan Hospital, Shanghai

200094

RECRUITING

Wusong Hospital, Zhongshan Hospital, Fudan University, Shanghai

201508

RECRUITING

Shanghai Jinshan Hospital, Shanghai

201700

RECRUITING

Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai

999077

RECRUITING

Health and Humanity Research Centre, Hongkong, China., Hong Kong

999078

RECRUITING

Dr. Stanley Ho Medical Foundation, Macao

RECRUITING

University Hospital, Macau University of Science and Technology., Macao

All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Shanghai Jinshan Hospital

OTHER

collaborator

Zhongshan Qingpu Hospital, Fudan University

UNKNOWN

collaborator

Zhongshan Wusong Hospital, Fudan University

UNKNOWN

collaborator

Macau University of Science and Technology Hospital

OTHER

collaborator

Health and Humanity Research Centre, Hongkong

UNKNOWN

collaborator

Dr. Stanley Ho Medical Foundation, Macau

UNKNOWN

lead

Yunfeng Cheng

OTHER